ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $107.3333.

A number of equities analysts have issued reports on ANIP shares. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Barclays started coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective for the company. Finally, Guggenheim upped their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th.

Insider Buying and Selling

In related news, SVP Ori Gutwerg sold 2,060 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $76.50, for a total transaction of $157,590.00. Following the sale, the senior vice president owned 84,782 shares of the company’s stock, valued at approximately $6,485,823. This trade represents a 2.37% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Stephen P. Carey sold 7,312 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $75.50, for a total value of $552,056.00. Following the transaction, the chief financial officer owned 185,543 shares in the company, valued at approximately $14,008,496.50. This represents a 3.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 27,860 shares of company stock worth $2,114,771 over the last ninety days. Insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Large investors have recently modified their holdings of the business. Hantz Financial Services Inc. lifted its holdings in shares of ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares in the last quarter. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at approximately $28,000. Newbridge Financial Services Group Inc. grew its position in shares of ANI Pharmaceuticals by 200.0% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 400 shares during the period. Kemnay Advisory Services Inc. bought a new stake in ANI Pharmaceuticals during the 4th quarter worth approximately $48,000. Finally, State of Wyoming bought a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $50,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Stock Down 1.8%

Shares of ANI Pharmaceuticals stock opened at $72.82 on Friday. The business has a fifty day simple moving average of $77.59 and a 200 day simple moving average of $83.86. The stock has a market cap of $1.63 billion, a PE ratio of 21.67 and a beta of 0.52. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11. ANI Pharmaceuticals has a 12 month low of $56.71 and a 12 month high of $99.50.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.